We describe a general way of introducing transgenes into the mouse germ line for comparing different sequences without the complications of variation in copy nuniber and insertion site. The method uses homologous recombination in embryonic stem (ES) cells to generate mice having a single copy of a transgene integrated into a chosen location in the genome. To test the method, a single copy murine bcl-2 cDNA driven by either a chicken 8-actin promoter or a human 18-actin promoter has been inserted immediately 5' to the X-linked hypoxanthine phosphoribosyltransferase locus by a directly selectable homologous recombination event. The level of expression of the targeted bcl-2 transgene in ES cells is identical in independently isolated homologous recombinants having the same promoter yet varies between the different promoters. In contrast, the expression of bcl-2 transgenes having the same (chicken ,B-actin) promoter varies drastically when they are independently integrated at random insertion sites. Both promoters direct broad expression of the single-copy transgene in mice derived from the respective targeted ES cells. In vitro and in vivo, the human f8-actin promoter consistently directed a higher level of transgene expression than the chicken f8-actin promoter.
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The generation of transgenic mice by the injection of DNA into the male pronucleus of one-cell murine embryos has proven to be an effective method of achieving expression of exogenous DNA sequences for many purposes, including overexpression, ectopic expression, mutant analysis, promoter analysis, delivery of toxins, and dominant/negative mutations (for review, see ref. 1). However, DNA incorporated into the mouse germ line using this method is integrated randomly and in unpredictable copy numbers. The integration site often has a profound effect on expression of the transgene. Furthermore, insertion of the transgene in or near another gene, particularly when the transgene insertion is made homozygous by breeding, can cause an undesired phenotype (2) . Thus, it is estimated that 5-10% of transgene integration events result in a mutant phenotype as a consequence of disruptions, deletions, or translocations (1, 3, 4) .
Targeting a single copy of a transgenic sequence to a chosen location in the genome would have many advantages: the ability to control copy number, the ability to insert the transgene into regions of chromatin compatible with a desired developmental and tissue-specific expression, and the exclusion of insertional mutagenesis as a contributor to the phenotype. Targeted transgenes should therefore provide a more efficient and informative means of securing and comparing the expression of various transgenic sequences than is available with current transgenic procedures.
Homologous recombination can, in principle, be used to target a transgene to any chosen locus in the genome. Consequently, by using homologous recombination in murine embryonic stem (ES) cells to integrate transgenic sequences into the genome at a chosen location followed by blastocyst injection of the modified cells, single-copy chosen-site transgenic mouse lines can be obtained. To test this rationale, we have introduced a transgene linked to two different promoters into the ubiquitously expressed murine hypoxanthine phosphoribosyltransferase (Hprt) locus. We made this choice because the Hprt gene is a housekeeping gene (5), so that any promoter inserted into the locus is not likely to be restricted in its expression by unfavorable chromatin configurations, and because of the availability of a targeting vector capable of mediating a highly efficient, directly selectable homologous recombination event at the Hprt locus (6).
MATERIALS AND METHODS
Targeting Vectors and Constructs. The targeting vector, pMP8SKB (Fig. 1A) , is a modification of pMP8 (6), made by removing an EcoRI site in the 3' homology region and a NotI site in the polylinker of the pBLUESCRIPT (Stratagene) backbone. To provide a "cassetting" site in the vector, a short linker containing a NotI site and an MluI site was inserted into the remaining EcoRI site at the downstream end of the 5' homology while preserving the EcoRI site. The transgenes were incorporated in the pMP8SKB targeting vector in the same transcriptional orientation as the downstream Hprt gene.
Two targeting constructs were made using the pMP8SKB vector. The pCBP8 targeting construct contained a 1640-bp transgenic cassette (upper line, Fig. 1B (Fig. 2C) . The other clones were products of replacement recombination event (Fig. 2F) . Exposure times were 5 days (bcl-2) and 5 h (actin). line 6-thioguanine resistant are well characterized and have been used to create a locus-specific targeting vector, pMP8 (6) . The targeting vector pMP8 includes sequences capable of restoring a functional Hprt gene following recombination so that homologous recombinants can be directly selected for in HAT medium. We modified pMP8 to give pMP8SKB, which is arranged to allow easy insertion of transgenic cassettes between the 5' homology sequences and the Hprt gene sequences (Fig. 1A) . The resulting targeting constructs were used for recombination-mediated introduction of a single copy of the transgenic sequences into the chosen site in the genome immediately upstream of a functional Hprt gene.
The targeting construct with the chicken 13-actin promoter was electroporated as a circular plasmid, a configuration favoring an insertional recombination event (see Fig. 2 E and F). The targeting construct with the human f3-actin promoter was linearized before electroporation, a configuration favoring a replacement event (see Fig. 2 B and C). Although these two mechanisms modify the locus in different ways, both result in complementation of the Hprt deletion and insertion of a single-copy of a transgenic cassette upstream of the Hprt gene sequences. Sequences downstream of the transgenes and up to 4 kb upstream of the transgenes are identical after both types of recombination event (Fig. 2 C and F) . Transgene Expression in ES Cells. Northern analysis was used to determine the expression of the targeted transgenes in ES cell lines. Fig. 3 is a Northern blot of total RNA from ES cell lines containing five independently targeted bcl-2 transgenes with the chicken j3-actin promoter (2A, 2B, 9A, 9B, and 9C) and five independently targeted bcl-2 transgenes with the human f3-actin promoter (6B, 8A, 8B, 8C, and 8D). The transgenic mRNAs were readily detected and were of the expected length, 1.1 kb. In all, a total of 15 independently derived clones of pCBP8 (chicken actin promoter) targeting were tested, and all had identical RNA expression levels in ES cells. The same was true for five independently derived clones of pHBP8 (human actin promoter) targeting. In addition, we detected no difference in the level of expression from targeted transgenes resulting from the two types of recombination event (compare 2B to 2A, 9A, 9B, 9C in Fig. 3 ). Thus independent targeting events involving either of the two transgenic cassettes result in identical expression in ES cells. Yet the unique characteristics of each transgene are readily detected, as illustrated in Fig. 3 which shows that expression of the bcl-2 transgene driven by from the chicken 63-actin promoter is consistently lower than expression of the bcl-2 transgene driven by the human ,B-actin promoter.
To directly compare the expression of a targeted transgene to that of the same transgene randomly integrated into the genome, the chicken ,B-actin promoter-containing transgene cassette was introduced into a vector that includes a neomycin resistance gene. The resulting construct, pCBPN (Fig. 1C) was then transfected into ES cells. Twenty-seven G418 resistant ES cell lines were generated. Fig. 4 is a northern blot of total RNA which compares expression from the two types of targeted transgene (2A having the chicken actin promoter and 8C having the human actin promoter) to that of 12 replicates of the randomly integrated chicken ,B-actin promoter transgene (A, E, F, G, H, J, K, N, P, T, V, W). Expression in the clones with randomly integrated transgenes was extremely variable, ranging from well below (E and W) the level of the targeted chicken promoter-driven targeted transgene (2A) to well above (T) the level of the human promoter-driven transgene (8C). (mRNA from the endogenous bcl-2 gene is greater than 7.5 kb in size because of a long 3' untranslated region. Due to the difficulty of preserving an mRNA of this length, the intensity of the endogenous band is not a reliable index of the amount of total RNA loaded per lane.) In all we tested 27 ES cell lines with randomly integrated constructs; of these 5 had high level expression of the bcl-2 transgene (illustrated by lanes K, P and T), 9 had intermediate level expression (illustrated by lanes J and V), and 13 had low level expression (illustrated by lanes A, E, F, G, H, N, and W). No correlation was observed between the level of expression and the number of copies of the transgene, as determined by Southern hybridization (data not shown). Thus, as has been reported by many previous investigators, the expression of the randomly integrated transgene varies drastically from replicate to replicate (Fig. 4) and is not directly related to copy number. In contrast, expression of replicates of each of the targeted transgenes are essentially invariant (Fig. 3) .
Generation of Transgenic Animals. To test the targeted transgenes in the whole animal, correctly targeted ES cells were injected into 3.5-day blastocyst-stage B6 embryos. The resultant male chimeras were bred to B6 females. Agouti pups from these crosses are 129/B6 F1 hybrids that have received the 129 ES cell genome. Because the Hprt gene is X-linked, all the female agouti mice are heterozygous for the targeted transgene but none of the agouti males are transgenic. The transgenic females can be used to generate hemizygous transgenic males, and interbreeding the transgenic males and females can then generate homozygous females.
Southern analysis demonstrated that the transgenic lines created by our targeting scheme have as expected, single-copy single-site transgenes. For this analysis, genomic DNA was digested with BamHI and hybridized with probes specific for either intron 3 of the Hprt locus (Fig. 5 Upper) or for bcl-2 (Fig.  S Lower) . The Hprt probe detects a 7-kb fragment in wild-type females and males and in the heterozygous females from the targeted lines; this fragment is from the wild-type Hprt locus on the strain B6-derived X chromosome. A fragment of 8. is detected in animals from the two targeted transgenic lines; this fragment corresponds to the transgenic X chromosome modified by homologous recombination with the two targeting constructs. (The 12.5-kb hybridizing fragment in DNA from the chicken 13-actin promoter line is from the upstream duplication of the 3' homology region generated during insertiontype replacement; see Fig. 2F .) Homozygous females and hemizygous males show only hybridizing fragments derived from the targeted Hprt locus.
The murine bcl-2 cDNA (Fig. 5 Lower) detects 1.5-and 12-kb fragments derived from the endogenous bcl-2 locus. The 5-kb and 9-kb fragments are from the targeted transgenes having the chicken actin and the human actin promoter, respectively. In every case, the hybridizing bands are of the predicted size for targeted events.
Expression of the Single-Copy bcl-2 Transgene in the Mouse. We compared the in vivo transcriptional activities of the two promoters adjacent to the reconstituted Hprt locus. As shown in Fig. 6 A and B (Top) , the chicken and human actin promoters both direct transgene expression in a wide variety of tissues, including bone marrow, brain, heart, thymus, kidney, spleen, and reproductive organs. Expression of the targeted transgene with the human f3-actin promoter is much higher than expression of the targeted transgene with the chicken ,B-actin promoter in all tissues, although less obvious in the hba-mbcl-2 bone marrow because of some degradation of the RNA. (Hybridization of the blots with a human ,-actin cDNA, Fig. 6 Bottom, provides a measure of amounts of RNA loaded.)
Sequential hybridization of the Northern blots used to prepare the top panels of Fig. 6 with a probe from the Hprt locus ( Fig. 6 A and B , Middle) revealed two points of interest. First, expression of the Hprt gene is greater when it is adjacent to the human f3-actin promoter than when next to the chicken f3-actin promoter. [Control heterozygous animals having a targeted Hprt locus with a nontranscribed transgene have Hprt expression similar to the transgenes with the chicken ,B-actin promoter (data not shown).] Second, the Hprt gene appears to be expressed in all tissues including the liver and kidney, two tissues with low or undetectable transgene expression.
As with many X-linked loci, the Hprt gene is transcriptionally silent on the inactivated X chromosome in females (14) (15) (16) . Consequently, in heterozygous females random inactivation of the transgene should occur early in development, although differential survival of the resulting cells might later skew the final cell population in either direction depending on whether the transgene is detrimental or beneficial. Northern analysis of transgene expression in heterozygous females, homozygous females, and hemizygous males suggests that the transgenes are randomly inactivated in females since homozygous females and hemizygous males have similar levels of transgene expression (data not shown). (If the transgenes did not undergo random inactivation, homozygous females would be expected to have two transcriptionally active transgenes and thus twice as much transgenic mRNA as a hemizygous male.) Given random inactivation in females, heterozygous females would be expected to have half the transgene expression of homozygous females. Yet, in the heterozygous and homozygous females with targeted bcl-2 transgenes, the relative levels of transgene expression vary from tissue to tissue, indicating differential survival of cells with active transgenic X chromosomes (data not shown).
DISCUSSION
We have described a method that uses homologous recombination in murine ES cells to generate mice having a single-copy of a transgene inserted at a chosen site in the genome. The method has been tested by inserting the murine bcl-2 gene with two different promoters (chicken ,B-actin and human ,B-actin) into the mouse genome adjacent to the Hprt locus in ES cells. choose the acceptor locus for the targeted transgene based on the tissue specificity of expression at that locus-e.g., the erythroid specificity of the ,3-globin locus (18)-or the liver specificity of the apolipoprotein Al/Clll locus (19) . Such choices would be expected to lead to useful interactions between the transgenes and regulatory elements at the target locus. Targeted transgenes inserted at a locus other than the Hprt locus will not usually be directly selectable. However, several methods have been described recently that enable the use of selection for repeated targeting of any locus (20) (21) (22) (23) . One of the methods, the plug and socket method, employs direct selection for Hprt function so that its adaptation for use in making chosen-site transgenes would retain the convenience we obtained here from use of the deleted Hprt locus in E14TG2a cells (21) .
The E14TG2a Hprt locus is, however, particularly useful for studying single-copy chosen-site transgenes for several reasons. First, the locus is directly selectable, so that the gene targeting experiment is no more difficult than a simple transfection experiment. Second, the Hprt gene is expressed in essentially all tissues and at virtually all developmental stages, indicating that it lies in a constitutively open chromatin region; accordingly, tissue and developmentally specific promoters and enhancers can be expected to retain their natural specificity when used to drive the targeted transgene. Third, the X-chromosomal location of the Hprt locus, coupled with the random inactivation of transgenes in heterozygous females but not in homozygous females or hemizygous males, provides an interesting way of determining the effects of the transgene in various tissues. It could even allow the generation of transgenic animals through the mosaic expression of a transgene that would be lethal when expressed in all tissues.
We suggest that our method of generating targeted transgenes will be generally useful and should facilitate the study of regulatory sequences in vivo and the development of mutant promoters having precise quantitative effects. Finally, we emphasize that the use of a chosen site for a single copy of a transgene avoids many of the problems associated with randomly inserted transgenes.
